BR112012018457A2 - peptídeos melk modificados e vacinas contendo os mesmos - Google Patents
peptídeos melk modificados e vacinas contendo os mesmosInfo
- Publication number
- BR112012018457A2 BR112012018457A2 BR112012018457A BR112012018457A BR112012018457A2 BR 112012018457 A2 BR112012018457 A2 BR 112012018457A2 BR 112012018457 A BR112012018457 A BR 112012018457A BR 112012018457 A BR112012018457 A BR 112012018457A BR 112012018457 A2 BR112012018457 A2 BR 112012018457A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- endometriosis
- nucleic acids
- melk
- modified
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 101150054634 melk gene Proteins 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000007792 addition Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11025—Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29799610P | 2010-01-25 | 2010-01-25 | |
| PCT/JP2011/000352 WO2011089921A1 (en) | 2010-01-25 | 2011-01-24 | Modified melk peptides and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012018457A2 true BR112012018457A2 (pt) | 2017-01-10 |
Family
ID=44306725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018457A BR112012018457A2 (pt) | 2010-01-25 | 2011-01-24 | peptídeos melk modificados e vacinas contendo os mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8871719B2 (enExample) |
| EP (1) | EP2528937B1 (enExample) |
| JP (1) | JP5884104B2 (enExample) |
| KR (1) | KR101841475B1 (enExample) |
| CN (1) | CN102822193B (enExample) |
| AU (1) | AU2011208271B2 (enExample) |
| BR (1) | BR112012018457A2 (enExample) |
| CA (1) | CA2787369A1 (enExample) |
| MX (1) | MX2012008657A (enExample) |
| RU (1) | RU2580035C2 (enExample) |
| SG (1) | SG182580A1 (enExample) |
| TW (1) | TWI485245B (enExample) |
| WO (1) | WO2011089921A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014005362A2 (pt) * | 2011-09-07 | 2017-06-13 | Immunotope Inc | vacinas de tumor com nanopartículas |
| JP6077544B2 (ja) * | 2011-09-07 | 2017-02-08 | ミダテック リミテッド | ナノ粒子−ペプチド組成物 |
| KR20140138900A (ko) | 2012-03-09 | 2014-12-04 | 온코세라피 사이언스 가부시키가이샤 | 펩티드를 포함한 의약 조성물 |
| TWI714869B (zh) * | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| ES2900004T3 (es) | 2013-08-05 | 2022-03-15 | Immatics Biotechnologies Gmbh | Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC) |
| AU2017318907B2 (en) * | 2016-08-31 | 2023-07-06 | Oncotherapy Science, Inc. | Monoclonal antibody against MELK and utilization thereof |
| AU2019384820B2 (en) * | 2018-11-21 | 2026-02-12 | Endomet Biosciences, Inc. | Compositions and methods for treating endometriosis |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| KR100209784B1 (ko) | 1996-10-08 | 1999-07-15 | 박원훈 | 인간 단백질 변이인산화효소 유전자(hpk 38), 그의 염기 서열, 효소 단백질 및 그의 아미노산 서열 |
| US6229001B1 (en) | 1997-01-03 | 2001-05-08 | Southern Research Institute | Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase |
| US6605709B1 (en) | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
| JP2003534786A (ja) | 2000-05-31 | 2003-11-25 | カイロン コーポレイション | 化学療法および放射線感作物質を用いた腫瘍性疾患を処置するための組成物および方法 |
| US6833447B1 (en) | 2000-07-10 | 2004-12-21 | Monsanto Technology, Llc | Myxococcus xanthus genome sequences and uses thereof |
| US20020156263A1 (en) | 2000-10-05 | 2002-10-24 | Huei-Mei Chen | Genes expressed in breast cancer |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| US20030157082A1 (en) | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| MXPA04012614A (es) | 2002-06-14 | 2005-12-14 | Diversa Corp | Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas. |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| CA3061769C (en) | 2003-06-24 | 2021-10-26 | Genomic Health, Inc. | Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer |
| JP2007502115A (ja) | 2003-08-14 | 2007-02-08 | エクセリクシス， インク． | ＲＡＣ経路のモディファイヤーとしてのＭＥＬＫｓおよび使用方法 |
| JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
| ATE491044T1 (de) | 2004-08-10 | 2010-12-15 | Oncotherapy Science Inc | Gene und polypeptide in verbindung mit brustkrebserkrankungen |
| US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| CA2598889A1 (en) | 2005-02-24 | 2006-08-31 | Cemines, Inc. | Compositions and methods for classifying biological samples |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| JP5095603B2 (ja) * | 2005-07-27 | 2012-12-12 | オンコセラピー・サイエンス株式会社 | 結腸癌関連遺伝子ｔｏｍ３４ |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
-
2011
- 2011-01-21 TW TW100102242A patent/TWI485245B/zh not_active IP Right Cessation
- 2011-01-24 WO PCT/JP2011/000352 patent/WO2011089921A1/en not_active Ceased
- 2011-01-24 KR KR1020127021961A patent/KR101841475B1/ko not_active Expired - Fee Related
- 2011-01-24 MX MX2012008657A patent/MX2012008657A/es active IP Right Grant
- 2011-01-24 AU AU2011208271A patent/AU2011208271B2/en not_active Ceased
- 2011-01-24 CA CA2787369A patent/CA2787369A1/en not_active Abandoned
- 2011-01-24 US US13/574,774 patent/US8871719B2/en active Active
- 2011-01-24 EP EP11734528.0A patent/EP2528937B1/en active Active
- 2011-01-24 JP JP2012549592A patent/JP5884104B2/ja active Active
- 2011-01-24 CN CN201180015963.3A patent/CN102822193B/zh active Active
- 2011-01-24 RU RU2012136464/10A patent/RU2580035C2/ru not_active IP Right Cessation
- 2011-01-24 BR BR112012018457A patent/BR112012018457A2/pt active Search and Examination
- 2011-01-24 SG SG2012052999A patent/SG182580A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8871719B2 (en) | 2014-10-28 |
| RU2012136464A (ru) | 2014-03-10 |
| AU2011208271A1 (en) | 2012-08-16 |
| CN102822193A (zh) | 2012-12-12 |
| KR20120127467A (ko) | 2012-11-21 |
| TW201130972A (en) | 2011-09-16 |
| CN102822193B (zh) | 2016-03-30 |
| MX2012008657A (es) | 2013-05-30 |
| CA2787369A1 (en) | 2011-07-28 |
| RU2580035C2 (ru) | 2016-04-10 |
| EP2528937B1 (en) | 2019-05-08 |
| JP5884104B2 (ja) | 2016-03-15 |
| AU2011208271B2 (en) | 2015-04-09 |
| SG182580A1 (en) | 2012-08-30 |
| TWI485245B (zh) | 2015-05-21 |
| US20130034574A1 (en) | 2013-02-07 |
| KR101841475B1 (ko) | 2018-03-23 |
| EP2528937A1 (en) | 2012-12-05 |
| JP2013517764A (ja) | 2013-05-20 |
| WO2011089921A1 (en) | 2011-07-28 |
| EP2528937A4 (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| EA201792044A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| EA201792484A1 (ru) | Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака | |
| EA201892021A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| CR20200434A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 5. 2018-74) | |
| EA201891759A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| EA201992664A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| CR20200596A (es) | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295) | |
| MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
| EP2528937A4 (en) | MODIFIED MELK-PEPTIDES AND VACCINES CONTAINING THEREOF | |
| JP2014502961A5 (enExample) | ||
| CR20200607A (es) | INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551) | |
| PH12017502234A1 (en) | Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| BR112012024997A2 (pt) | peptídeos ect2 e vacinas incluindo os mesmos | |
| MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
| BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
| EA202190241A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака | |
| EA202190465A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
| EA202092502A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака | |
| EA202092543A3 (ru) | Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака | |
| EA202091864A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21/11/2018. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |